Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-09-21

Clinical Trial Update: Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a topical anti-angiogenic therapy for hereditary hemorrhagic telangiectasia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Unity Health Toronto | Conditions: Hereditary Hemorrhagic Telangiectasia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-09-21